Immune checkpoint inhibitor‐induced lichenoid drug eruption‐sparing scar burns-Reference-Cited by-同舟云学术

Immune checkpoint inhibitor‐induced lichenoid drug eruption‐sparing scar burns

Published:2023-11-27 Issue: Volume: Page:
ISSN:0004-8380
Container-title:Australasian Journal of Dermatology
language:en
Short-container-title:Aust J Dermatology

Author:

Truong Kelvin¹²^ORCID,Chamberlin Charmaine Vanessa¹^ORCID,Kim Jennifer²³^ORCID,Carlino Matteo S.²⁴⁵^ORCID,Araujo Raquel Ruiz¹²^ORCID

Affiliation:

1. Department of Dermatology Westmead Hospital Westmead New South Wales Australia

2. Sydney Medical School The University of Sydney Camperdown New South Wales Australia

3. Department of Tissue Pathology and Diagnostic Oncology, Institute of Clinical Pathology and Medical Research (ICPMR) Westmead Hospital NSW Health Pathology Westmead New South Wales Australia

4. Department of Medical Oncology, Crown Princess Mary Cancer Centre Westmead Hospital Sydney New South Wales Australia

5. Melanoma Institute Australia Sydney New South Wales Australia

Abstract

AbstractThe authors present a striking case of a patient experiencing a lichenoid drug eruption secondary to immunotherapy, curiously sparing scarred skin from past burns. We observed vastly higher amounts of inflammatory lymphoid cells staining for PD‐1; 70% in skin with a lichenoid drug reaction and 50% in scarred skin. The lack of a lichenoid reaction at sites of scarred skin may indicate that a basement membrane component may be causative for a lichenoid drug eruption.

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajd.14192

Reference7 articles.

1. Gene expression profiling of lichenoid dermatitis immune‐related adverse event from immune checkpoint inhibitors reveals increased CD14 + and CD16 + monocytes driving an innate immune response

2. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy

3. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy

4. Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes

5. Lichen Planus in Irradiated Skin During Nivolumab Treatment